Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (381)	2/26/1999 12:19:00 PM
From: aknahow	Respond to of 712

O.K. we all saw this but just for the record: MADISON, N.J. (CBS.MW) -- A European committee has recommended approval of two Schering-Plough Corp. drugs, one for hepatitis C and another for heart conditions, the company said Friday. A committee for the European Agency for the Evaluation of Medicinal Products issued positive opinions of the pharmaceutical company's (SGP) Rebetol (ribavirin) capsules to treat patients with chronic hepatitis C, a potentially deadly liver disease, and its Integrilin drug for the prevention of acute coronary syndrome, a serious heart condition, the company said. The committee's opinion serves as the basis for a European Commission approval, which is typically issued four months later. In addition we all knew it was coming.

To: LLCF who wrote (381)	3/1/1999 10:17:00 AM
From: aknahow	Respond to of 712

The ugly, the bad and the good! What's ugly is Schering has exclusive rights to Europe. The bad is shareholders do not know how long CORR will receive only an undisclosed royalty on European sales. The good is whatever the royalty is it will drop right to the bottom line. Less is more? Eventually CORR becomes a partner and will share in the net profits. All of this was disclosed in the annual report. Unfortunately, I had forgotten it and the CORR press release took me by surprise.